David Miklos
Hematology · Stanford Health Care
Credentials: · ·
History
- 1998–2001
- 1996–1998
Brigham and Women's Hospital Harvard Medical School (1996) MA
- 1993–1996
Brigham and Women's Hospital Harvard Medical School (1996) MA
1991–1995
Research
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
New England Journal of Medicine · 2017 · 4,914 citations
The Lancet Oncology · 2019 · 1,921 citations
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
New England Journal of Medicine · 2020 · 1,512 citations
53 papers
46 papers
44 papers · 2 as a fellow
44 papers
43 papers
42 papers
40 papers
39 papers
Grants
- 1997–2030
Bone Marrow Grafting and Cellular Therapy for Leukemia and Lymphoma
National Cancer Institute · P01
PI · $7.7M · Stanford University
- 2016
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplants (HCT)
National Cancer Institute · U54
Project lead · $717.3K · Fred Hutchinson Cancer Research Center
- 2009–2014
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplants (HCT)
National Institute of Allergy and Infectious Diseases · U54
Project lead · $468.5K · Fred Hutchinson Cancer Research Center
- 2007–2010
Microarray Analysis of H-Y Antibodies in Human Transplantation
National Heart, Lung, and Blood Institute · R21
Contact PI · $433.9K · Stanford University
Clinical trials
- 2021–2023
18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
Principal investigator · Terminated · Phase 1
Stanford University
- 2010–2013
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Principal investigator · Completed · Phase 1
Stanford University
- 2008–2012
A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease
Principal investigator · Completed · Phase 1
David Miklos
- 2006–2014
Principal investigator · Completed
Stanford University